SI-BONE Inc
Mika Nishimura has nearly 30 years of experience in medical technology, serving in a variety of operational and executive capacities. Ms. Nishimura is currently an Operational Partner with Gilde Healthcare Partners, a life-science focused venture fund. She also serves as a board member for Accuray, Inc. (NASDAQ: ARAY) and as a board advisor to Tristel, plc, a UK public medical device company. From 2016 to 2020, Ms. Nishimura served as Vice President of Commercialization at nVision Medical Corporation, an early clinical-stage medical device company acquired by Boston Scientific. Previously, she served as Vice President, Commercial Development at Auxogyn, a medical technology company, acquired by Progyny, Inc. Earlier in her career, Ms. Nishimura served as Vice President of International Sales Operations and Marketing at ev3 Inc., where she held P&L responsibilities for the emerging markets. Ms. Nishimura has an MBA from Harvard Graduate School of Business Administration and a B.A. in Economics from Yale University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
SI-BONE Inc
2 followers
SI-BONE, Inc. is focused on development of medical devices. The Company is engaged in the development, manufacture and commercialization of minimally invasive surgical devices for the treatment of patients with low back symptoms related to certain sacroiliac (SI) joint disorders. The Company offers iFuse Implant System, which provides a minimally invasive surgical solution to fuse the SI joint using patented triangular titanium implants that create an interference fit within the ilium and sacrum. The triangular implant shape, combined with the press fit insertion, is designed to provide fixation by minimizing rotational motion. The implants has a porous surface that provide an environment for bone ongrowth and ingrowth, facilitating long-term fusion of the joint. The iFuse Implant System is intended for sacroiliac fusion for conditions, including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.